Ratan Tata-backed Axio Biosolution Launches MaxioCel, Cutting-Edge Innovation in Advance Wound Care
Summary
However, there are no products in wound care management that provide substantial relief from the high levels of discomfort and pain endured by patients. The medical fraternity needs to embrace technological innovations happening in advance wound care management space in order to improve the quality of life of patients with chronic wounds.” Leo Mavely, CEO, Axio Biosolutions, further added, “With the latest addition of MaxioCel to our product portfolio, we now have a complete range of innovative products spanning pre-hospital, intra-operative and post-operative clinical needs. We are proud to bring this product as an Indian innovation in wound care for the world market.” Axio Biosolutions is a medtech company with focus on biomaterials. Last year, Axio Biosolutions raised $7.4mn in a Series B funding round led by Ratan Tata’s UC- RNT, along with existing investors Accel Partners and IDG Ventures India. Axio’s customers also include numerous government hospitals and reputed private institutions such as AIIMS, Manipal, Apollo, Breach Candy and Fortis among others.
Classifications
AskAI Classifications
LabelsLinked Companies
